Press release
Blood Cancer Drugs Market Outlook 2025-2034: Key Trends, Growth Drivers, and Market Share
How Big Is the Blood Cancer Drugs Market Expected to Be, and What Will Its Growth Rate Be?In recent times, the market size for blood cancer drugs has significantly expanded. It is projected to rise from $74.78 billion in 2024 to $80.79 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. The previous growth can be traced back to advancements in research and development, an ageing demographic, heightened awareness and early diagnosis, along with regulatory approvals.
Anticipated to witness robust growth in the coming years, the size of the blood cancer drugs market is set to expand to $106.8 billion in 2029, experiencing a compound annual growth rate (CAGR) of 7.2%. Factors such as an uptick in disease incidence, the emergence of new markets, and supportive care contribute to this growth in the projected period. The forecast period will see key trends like investments in research and development, therapies combining multiple treatments, identification of biomarkers, advancements in immunotherapy, and the growth of personalized medicine.
What Are the Primary Growth Drivers for the Blood Cancer Drugs Market?
The escalating prevalence and growing mortality rates linked to blood cancer worldwide act as catalysts propelling the blood cancer drugs market. Various forms of blood cancer such as leukemia, lymphoma, myeloma, and others, each with their own unique risk factors, can either be managed, prevented through medication therapies, or could potentially be fatal. According to a report by Bristol-Myers Squibb Company in November 2022, the forecast for new blood cancer diagnoses worldwide in 2040 is set at over 1.85 million. This includes 918,872 lymphoma cases, 656,345 cases of leukemia, and 275,047 myeloma cases. In addition, the report predicts an estimated 1,100,000 deaths worldwide from blood cancer in 2040. The rising mortality rates and escalating incidences of blood cancer globally, are significant factors propelling the blood cancer drugs market.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp
Who Are the Dominant Companies Influencing Blood Cancer Drugs Market Trends?
Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated
How Is the Blood Cancer Drugs Market Evolving?
Key players within the blood cancer drugs market are aiming to edge out rivals by innovating new drugs and seeking FDA approval. The approval by the FDA, also known as the United States Food and Drug Administration, gives legal sanction to pharmaceutical products to be sold in the United States. For example, in March 2024, Bristol Myers Squibb, a company from the pharmaceutical industry in the US, was awarded FDA approval for its premier and sole CAR T-cell therapy for adults suffering from recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This fast-track approval paves the way for its use in patients who have already had at least two prior treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. From the TRANSCEND CLL 004 trial, it was shown that Breyanzi had a complete response rate of 20% and a median duration of response of 35.3 months for those who responded.
What Are the Different Segmentations in the Blood Cancer Drugs Market?
The blood cancer drugs market covered in this report is segmented -
1) By Blood Cancer Type: Leukemia, Lymphoma
2) By Drugs: Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs
3) By Treatment Approaches: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic
Subsegments:
1) By Leukemia: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Other Types of Leukemia
2) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Other Types of Lymphoma
Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
Which Region Is at the Forefront of the Blood Cancer Drugs Market?
North America was the largest region in the blood cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Is Covered In The Blood Cancer Drugs Global Market Report?
- Market Size Analysis: Analyze the Blood Cancer Drugs Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Blood Cancer Drugs Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Blood Cancer Drugs Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Blood Cancer Drugs Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2587
Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Blood Cancer Drugs Market Outlook 2025-2034: Key Trends, Growth Drivers, and Market Share here
News-ID: 3870555 • Views: …
More Releases from The Business Research Company

Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…

Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…

Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…

Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for Drug
Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming…
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage
Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic…
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights:
* Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029
* Global and Regional Antibody Drug Conjugate Market Insight
* Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023
* Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight
* Insight On Antibody Drug Conjugates In Clinical Trials: > 550…
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…